Statins as a preventative therapy for venous thromboembolism

Alex Wallace, Hassan Albadawi, Peter Hoang, Andrew Fleck, Sailendra Naidu, Grace Knuttinen, Rahmi Oklu

Research output: Contribution to journalReview article

Abstract

The anti-inflammatory effects of statins have likely not been used to their fullest extent, particularly in reducing venous thromboembolic events. Current therapy for thrombotic events hinges on anticoagulation via heparin, warfarin or new oral anticoagulants. Interventional procedures with thrombectomy may also play a critical role. Unfortunately, thrombotic events can occur and recur despite meticulous anticoagulation therapy. Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), two complicated and prevalent diseases that can cause chronic disease states such as post-thrombotic syndrome (PTS). In 2009 the JUPITER trial demonstrated that rosuvastatin may be effective when dealing with vascular inflammation by providing an anti-inflammatory effect. Multiple subsequent studies have looked at this association with some promising findings. The mechanism of action for statins is not entirely understood but there has been a variety of proposals and subsequent testing of inflammatory biomarkers. Additional prospective trials are needed to confirm the possible benefit of VTE reduction through an anti-inflammatory effect, but if this can be shown then statins may become a safe adjunctive therapy for VTE prevention.

Original languageEnglish (US)
Pages (from-to)S207-S218
JournalCardiovascular Diagnosis and Therapy
Volume7
DOIs
StatePublished - Dec 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Venous Thromboembolism
Anti-Inflammatory Agents
Thrombectomy
Warfarin
Pulmonary Embolism
Venous Thrombosis
Anticoagulants
Blood Vessels
Heparin
Chronic Disease
Therapeutics
Biomarkers
Inflammation

Keywords

  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Pulmonary embolism (PE)
  • Thromboembolism
  • Venous thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statins as a preventative therapy for venous thromboembolism. / Wallace, Alex; Albadawi, Hassan; Hoang, Peter; Fleck, Andrew; Naidu, Sailendra; Knuttinen, Grace; Oklu, Rahmi.

In: Cardiovascular Diagnosis and Therapy, Vol. 7, 01.12.2017, p. S207-S218.

Research output: Contribution to journalReview article

@article{3089e806e47a4c889b4e2aeb1583bac1,
title = "Statins as a preventative therapy for venous thromboembolism",
abstract = "The anti-inflammatory effects of statins have likely not been used to their fullest extent, particularly in reducing venous thromboembolic events. Current therapy for thrombotic events hinges on anticoagulation via heparin, warfarin or new oral anticoagulants. Interventional procedures with thrombectomy may also play a critical role. Unfortunately, thrombotic events can occur and recur despite meticulous anticoagulation therapy. Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), two complicated and prevalent diseases that can cause chronic disease states such as post-thrombotic syndrome (PTS). In 2009 the JUPITER trial demonstrated that rosuvastatin may be effective when dealing with vascular inflammation by providing an anti-inflammatory effect. Multiple subsequent studies have looked at this association with some promising findings. The mechanism of action for statins is not entirely understood but there has been a variety of proposals and subsequent testing of inflammatory biomarkers. Additional prospective trials are needed to confirm the possible benefit of VTE reduction through an anti-inflammatory effect, but if this can be shown then statins may become a safe adjunctive therapy for VTE prevention.",
keywords = "Hydroxymethylglutaryl-CoA reductase inhibitors, Pulmonary embolism (PE), Thromboembolism, Venous thrombosis",
author = "Alex Wallace and Hassan Albadawi and Peter Hoang and Andrew Fleck and Sailendra Naidu and Grace Knuttinen and Rahmi Oklu",
year = "2017",
month = "12",
day = "1",
doi = "10.21037/cdt.2017.09.12",
language = "English (US)",
volume = "7",
pages = "S207--S218",
journal = "Cardiovascular Diagnosis and Therapy",
issn = "2223-3652",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Statins as a preventative therapy for venous thromboembolism

AU - Wallace, Alex

AU - Albadawi, Hassan

AU - Hoang, Peter

AU - Fleck, Andrew

AU - Naidu, Sailendra

AU - Knuttinen, Grace

AU - Oklu, Rahmi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The anti-inflammatory effects of statins have likely not been used to their fullest extent, particularly in reducing venous thromboembolic events. Current therapy for thrombotic events hinges on anticoagulation via heparin, warfarin or new oral anticoagulants. Interventional procedures with thrombectomy may also play a critical role. Unfortunately, thrombotic events can occur and recur despite meticulous anticoagulation therapy. Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), two complicated and prevalent diseases that can cause chronic disease states such as post-thrombotic syndrome (PTS). In 2009 the JUPITER trial demonstrated that rosuvastatin may be effective when dealing with vascular inflammation by providing an anti-inflammatory effect. Multiple subsequent studies have looked at this association with some promising findings. The mechanism of action for statins is not entirely understood but there has been a variety of proposals and subsequent testing of inflammatory biomarkers. Additional prospective trials are needed to confirm the possible benefit of VTE reduction through an anti-inflammatory effect, but if this can be shown then statins may become a safe adjunctive therapy for VTE prevention.

AB - The anti-inflammatory effects of statins have likely not been used to their fullest extent, particularly in reducing venous thromboembolic events. Current therapy for thrombotic events hinges on anticoagulation via heparin, warfarin or new oral anticoagulants. Interventional procedures with thrombectomy may also play a critical role. Unfortunately, thrombotic events can occur and recur despite meticulous anticoagulation therapy. Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), two complicated and prevalent diseases that can cause chronic disease states such as post-thrombotic syndrome (PTS). In 2009 the JUPITER trial demonstrated that rosuvastatin may be effective when dealing with vascular inflammation by providing an anti-inflammatory effect. Multiple subsequent studies have looked at this association with some promising findings. The mechanism of action for statins is not entirely understood but there has been a variety of proposals and subsequent testing of inflammatory biomarkers. Additional prospective trials are needed to confirm the possible benefit of VTE reduction through an anti-inflammatory effect, but if this can be shown then statins may become a safe adjunctive therapy for VTE prevention.

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Pulmonary embolism (PE)

KW - Thromboembolism

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85038610076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038610076&partnerID=8YFLogxK

U2 - 10.21037/cdt.2017.09.12

DO - 10.21037/cdt.2017.09.12

M3 - Review article

AN - SCOPUS:85038610076

VL - 7

SP - S207-S218

JO - Cardiovascular Diagnosis and Therapy

JF - Cardiovascular Diagnosis and Therapy

SN - 2223-3652

ER -